The association of genetic factors with serum calretinin levels in asbestos-related diseases

Abstract

Background. Asbestos exposure is associated with different asbestos-related diseases, including malignant mesothelioma (MM). MM diagnosis is confirmed with immunohistochemical analysis of several markers, including calretinin. Increased circulating calretinin was also observed in MM. Our aim was to determine if CALB2 polymorphisms or polymorphisms in genes that can regulate calretinin expression are associated with serum calretinin levels or MM susceptibility.

Patients and methods. Our study included 288 MM patients and 616 occupationally asbestos-exposed subjects without MM (153 with asbestosis, 380 with pleural plaques and 83 without asbestos-related disease). Subjects were genotyped for seven polymorphisms in CALB2, E2F2, MIR335, NRF1 and SEPTIN7 genes using competitive allele-specific PCR. Serum calretinin was determined with ELISA in 545 subjects. Nonparametric tests, logistic regression and ROC curve analysis were used for statistical analysis.

Results. Carriers of at least one polymorphic CALB2 rs889704 allele had lower calretinin levels (P=0.036). Carriers of two polymorphic MIR335 rs3807348 alleles had higher calretinin (P=0.027), while carriers of at least one polymorphic NRF1 rs13241028 allele had lower calretinin levels (P=0.034) in subjects without MM. Carriers of two polymorphic E2F2 rs2075995 alleles were less likely to develop MM (OR=0.64, 95% CI=0.43-0.96, P=0.032), but the association was no longer significant after adjustment for age (P=0.093). Optimal serum calretinin cut-off values differentiating MM patients from other subjects differed according to CALB2, NRF1, E2F2, and MIR335 genotypes.

Conclusions. Our results suggest that genetic variability could influence serum calretinin levels. These findings could contribute to a better understanding of calretinin regulation and potentially to earlier MM diagnosis.